EDITOR'S PICKS

More>>
LATEST MOST VIEWED: LAST ONE YEAR MOST VIEWED: LAST TWO YEARS MOST DOWNLOADED
  • image
    Review| Open Access

    Stemness features in liver cancer

    Margherita Correnti, Richell Booijink, Giovanni Di Maira, Chiara Raggi, Fabio Marra

    Heterogeneity is a cardinal hallmark of cancer, including primary liver cancer (PLC), and occurs at different layers including putative cell-of-origin. Current evidence suggests that within cellular subpopulations in PLC there are stem-like cells, the cancer stem cells (CSCs). The CSC concept has... Read more

    This article belongs to the Special Issue New Insights in Liver Cancer Hepatoma Res 2018;4:69. | doi:10.20517/2394-5079.2018.96
    Published on: 5 Nov 2018  | Viewed:177  | Downloaded:9
    +HTML| PDF
  • image
    Review| Open Access

    Minimally invasive therapies for hepatocellular carcinoma: narrowing the gaps

    Kevin M. Sullivan, Raymond S. Yeung

    With increasing awareness of the HCC epidemic around the globe, early diagnosis of tumors provides a greater opportunity to benefit patients from liver-directed treatments including surgical resection, ablation, catheter-based therapies and external beam radiation. Development of new approaches... Read more

    This article belongs to the Special Issue Management of Hepatocellular Carcinoma Hepatoma Res 2018;4:68. | doi:10.20517/2394-5079.2018.95
    Published on: 25 Oct 2018  | Viewed:400  | Downloaded:17
    +HTML| PDF
  • image
    Original Article| Open Access

    Gender differences in hepatocellular cancer: disparities in nonalcoholic fatty liver disease/steatohepatitis and liver transplantation

    Eric M. Wu, Linda L. Wong, Brenda Y. Hernandez, Jun-Fang Ji, Wei Jia, Sandi A. Kwee, Sumodh Kalathil

    Aim: Worldwide, hepatocellular cancer (HCC) is the fourth leading cause of cancer death and occurs 3 times more commonly in males than females. Current surveillance practices do not fully address gender differences in HCC. Methods: Clinical characteristics and survival were compared between males... Read more

    Hepatoma Res 2018;4:66. | doi:10.20517/2394-5079.2018.87
    Published on: 18 Oct 2018  | Viewed:670  | Downloaded:14
    +HTML| PDF
  • image
    Original Article| Open Access

    Endolymphatic immunotherapy for advanced hepatocellular carcinoma: an update of our experience

    Marialuisa Lugaresi, Yuval Katz, Riccardo Bertelli, Noa Ruhrman, Lorenza Puviani, Giuseppe Cavallari, Caterina De Vinci, Giancarlo Pizza, Bruno Nardo

    Aim: We report an update of our experience on endolymphatic immunotherapy in patients with advanced hepatocellular carcinoma (HCC) not eligible for surgery. Methods: From 2003 to 2009 we enrolled 39 patients with advanced HCC not suitable for surgery. Patients underwent monthly endolymphatic... Read more

    This article belongs to the Special Issue Management of Hepatocellular Carcinoma Hepatoma Res 2018;4:67. | doi:10.20517/2394-5079.2018.88
    Published on: 18 Oct 2018  | Viewed:295  | Downloaded:9
    +HTML| PDF
  • image
    Review| Open Access

    New and old biomarkers of hepatocellular carcinoma

    Georgios Zacharakis, Ahmad Aleid, Khaled K Aldossari

    Hepatocellular carcinoma (HCC) is a significant cause of mortality in patients with chronic liver disease around the world. Development of biomarkers for early HCC detection is a primary public health goal to decrease mortality. The ideal biomarkers should be highly sensitive and specific for... Read more

    This article belongs to the Special Issue Management of Hepatocellular Carcinoma Hepatoma Res 2018;4:65. | doi:10.20517/2394-5079.2018.76
    Published on: 17 Oct 2018  | Viewed:507  | Downloaded:56
    +HTML| PDF
  • image
    Review| Open Access

    HCV elimination: breaking down the barriers to prison based care

    Timothy Papaluca, Alexander Thompson

    Hepatitis C virus (HCV) remains a major public health threat worldwide, responsible for 500,000 deaths annually; hepatocellular carcinoma (HCC) remains one of the major causes of HCV-related mortality. The global prevalence of HCV is approximately 1.0%, and in developed countries, injecting drug... Read more

    This article belongs to the Special Issue What More We can do on Hepatitis C? Hepatoma Res 2018;4:64. | doi:10.20517/2394-5079.2018.53
    Published on: 17 Oct 2018  | Viewed:422  | Downloaded:13
    +HTML| PDF
  • image
    Review| Open Access

    Alpha-fetoprotein as a predictor of hepatocellular carcinoma recurrence following liver transplantation

    Evangelia M. Fatourou, Abid R. Suddle, Michael A. Heneghan

    Alpha-fetoprotein (AFP) has been increasingly recognised as a valuable marker in predicting HCC recurrence post-liver transplantation. Moreover, its secretion has been associated with poor histological tumour characteristics as it reflects an aggressive tumour biological behaviour. This review... Read more

    This article belongs to the Special Issue Management of Hepatocellular Carcinoma Hepatoma Res 2018;4:63. | doi:10.20517/2394-5079.2018.62
    Published on: 10 Oct 2018  | Viewed:560  | Downloaded:32
    +HTML| PDF
  • image
    Review| Open Access

    Liver transplantation for hepatocellular carcinoma - non-cancer factors and implications for improving outcome beyond standard tumor criteria

    Arno Kornberg, Martina Schernhammer

    Liver transplantation (LT) is recognized as best treatment option in patients with early hepatocellular cancer (HCC) in underlying liver cirrhosis. Apart from tumor size and number implemented in the Milan criteria, which are current worldwide standards for patient selection, several biological... Read more

    This article belongs to the Special Issue Management of Hepatocellular Carcinoma Hepatoma Res 2018;4:60. | doi:10.20517/2394-5079.2018.86
    Published on: 29 Sep 2018  | Viewed:519  | Downloaded:19
    +HTML| PDF
  • image
    Original Article| Open Access

    Quantitative hepatitis B surface antigen in predicting recurrence of hepatitis B-related hepatocellular carcinoma after liver transplantation

    James Fung, Danny Ka-Ho Wong, Yasuhito Tanaka, Regina Lo, Tiffany Wong, Kenneth Siu-Ho Chok, Albert Chi-Yan Chan, Tan-To Cheung, Wing-Chiu Dai, Kelvin Ng, Kevin Ng, Man Kwan, Irene Ng, Wai-Kay Seto, Ching-Lung Lai, Man-Fung Yuen, Chung-Mau Lo

    Aim: Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) for chronic hepatitis B (CHB) can be associated with reappearance of hepatitis B surface antigen (HBsAg). The current study determined the significance of HBsAg qualitatively and quantitatively using a highly... Read more

    Hepatoma Res 2018;4:62. | doi:10.20517/2394-5079.2018.92
    Published on: 29 Sep 2018  | Viewed:541  | Downloaded:26
    +HTML| PDF
  • image
    Original Article| Open Access

    Novel diagnosis and therapy for hepatoma targeting HBV-related carcinogenesis through alternative splicing of FIR (PUF60)/FIRΔexon2

    Kazuyuki Matsushita, Tyuji Hoshino

    Aim: Disturbed alternative splicing of far upstream element-binding protein-interacting repressor (FIR) was found to be unable to repress c-Myc transcription and so it might be important for suppressing tumor development. FIR is a splicing variant of poly (U)-binding-splicing factor (PUF60), and... Read more

    This article belongs to the Special Issue Management of Hepatocellular Carcinoma Hepatoma Res 2018;4:61. | doi:10.20517/2394-5079.2018.81
    Published on: 29 Sep 2018  | Viewed:639  | Downloaded:30
    +HTML| PDF
+MoreView all articles
Subscribe

To receive email updates about the journal, please subscribe here.

News More>>
Partners
Copyright © 2018 OAE Publishing Inc. All Rights Reserved.